On Thursday, HomeStreet Inc (NASDAQ:HMST)’s shares declined -0.80% to $23.62.
HomeStreet Inc (HMST) the parent company of HomeStreet Bank, will conduct a quarterly earnings conference call on Monday, July 27, 2015 at 1:00 p.m. EDT. Mark K. Mason, president and CEO, will talk about second quarter 2015 results and provide an update on recent activities. A question and answer session will follow the presentation. Shareholders, analysts and other interested parties may register in advance at http://dpregister.com/10067115 or may join the call by dialing 1-877-508-9589 (1-855-669-9657 in Canada) shortly before 1:00 p.m. EDT. A rebroadcast will be accessible about one hour after the conference call by dialing 1-877-344-7529 and entering passcode 10067115.
HomeStreet, Inc., together with its auxiliaries, provides various financial services primarily in the Pacific Northwest, California, and Hawaii. The company operates in two segments, Commercial and Consumer Banking, and Mortgage Banking. The Commercial and Consumer Banking segment offers deposit products; residential, consumer, and business portfolio loans; non-deposit investment products; insurance products; and cash administration services.
Green Plains Inc (NASDAQ:GPRE)’s shares dropped -7.82% to $28.52.
Green Plains Inc (GPRE) declared the pricing of its initial public offering of 10,000,000 common units representing limited partner interests at a public offering price of $15.00 per common unit. The common units are expected to begin trading on the Nasdaq Global Market under the ticker symbol “GPP” on June 26, 2015. In addition, Green Plains Partners has granted the underwriters an option to purchase up to an additional 1,500,000 common units at the initial public offering price. The offering is expected to close on July 1, 2015, subject to the satisfaction of customary closing conditions.
Green Plains Inc. produces, markets, and distributes ethanol in the United States. The company operates through four segments: Ethanol Production, Corn Oil Production, Agribusiness, and Marketing and Distribution. It produces ethanol and co-products, such as wet, modified wet, or dried distillers grains, in addition to extracts non-edible corn oil that is used as feedstock for biodiesel, livestock feed additives, rubber substitutes, rust preventatives, inks, textiles, soaps, and insecticides.
At the end of Thursday’s trade, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)‘s shares dipped -4.47% to $12.82.
Vanda Pharmaceuticals Inc. (VNDA) presented positive results from the long-term maintenance REPRIEVE (Relapse prevention study in patients with schizophrenia) clinical study at the 2015 American Society of Clinical Pharmacology (ASCP) Annual Meeting in Miami Beach, Florida. The REPRIEVE study demonstrated the ability of Fanapt® (iloperidone) to prevent relapse or impending relapse in adult patients with schizophrenia as contrast to placebo. In the REPRIEVE study, 79.6% of patients treated with Fanapt® remained relapse free contrast to 36.6% for placebo-treated patients. Vanda intends to file a supplemental New Drug Application (sNDA) for Fanapt® with the U.S. Food and Drug Administration (FDA) in the second half of 2015 to comprise the results from the REPRIEVE study in the Fanapt® package insert.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companys products comprise HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also comprise Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
